Acura Pharmaceuticals, Inc. is a drug delivery company, which engages in the research, development, and commercialization of technologies and products intended to address safe use of medications. The company is headquartered in Palatine, Illinois. The company went IPO on 2000-09-12. Its platform technologies include LIMITX Technology, AVERSION Technology, and IMPEDE Technology. Its LIMITX Technology is designed to minimize the risks and side effects associated with overdose by retarding the release of active drug ingredients when too many tablets are accidentally or purposefully ingested. The LIMITX Technology is in development with hydrocodone bitartrate and acetaminophen (also known as LTX-03) as the lead product candidates. Its AVERSION Technology is to address methods of product tampering associated with opioid abuse by incorporating gelling ingredients and irritants into tablets to discourage abuse by snorting and provide barriers to abuse by injection. Its IMPEDE Technology is directed at minimizing the extraction and conversion of pseudoephedrine tablets into methamphetamine.
Follow-Up Questions
Acura Pharmaceuticals Inc의 CEO는 누구입니까?
Mr. Robert Jones은 2008부터 회사에 합류한 Acura Pharmaceuticals Inc의 President입니다.
ACUR 주식의 가격 성능은 어떻습니까?
ACUR의 현재 가격은 $0.0002이며, 전 거래일에 decreased 0% 하였습니다.
Acura Pharmaceuticals Inc의 주요 사업 주제나 업종은 무엇입니까?
Acura Pharmaceuticals Inc은 Pharmaceuticals 업종에 속하며, 해당 부문은 Health Care입니다
Acura Pharmaceuticals Inc의 시가총액은 얼마입니까?
Acura Pharmaceuticals Inc의 현재 시가총액은 $13269.999800000001입니다
